Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program

University of Toronto

$120,000.00

Molecular pathogenesis of BRCA1-associated and triple-negative breast cancer: mechanism of tissue specificity and identification and characterization of cooperating tumorigenic pathways.

FY 2009-10

Summary
Breast cancer affects almost 23 000 Canadian women each year, and remains a major cause of death. Five percent all breast cancers, and 80% of inherited cases, are caused by mutations in the BRCA1 gene. Women who carry these mutations are also at high risk for the development of ovarian cancer, but not tumors at other sites. The reasons why individuals with these mutations develop cancers in these specific organs may be related to estrogen activity, but the mechanism of this process is not clear. Furthermore, abnormalities in BRCA1 function are found in a significant proportion of non-inherited breast cancers. They are especially common in a subset of tumors that do not respond to currently available targeted therapies (hormone therapies like tamoxifen, and treatments directed against HER2/neu, an abnormal tumor cell protein ie. Herceptin). The goals of this project are therefore to: (1) elucidate the molecular factors that contribute to the predisposition to breast and ovarian cancers in women who carry BRCA1 gene mutations; and (2) identify other molecular abnormalities that could be targeted for the treatment and/or prevention of these tumors. My research will use an animal model of BRCA1-associated breast cancer to explore these questions, and incorporate RNA interference (RNAi), a powerful new tool in molecular biology, to identify candidates for further characterization, validation, and study in patient samples. Collaboration with our clinical and drug development programs will enable us to use this model to explore new leads for future drug development in this population. This bench-to-bedside approach may result in effective new treatments for these difficult-to-treat cancers, potentially leading to improved survival or cure for women with this disease.
Program
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
194162
Name
Cescon David W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Molecular pathogenesis of BRCA1-associated and triple-negative breast cancer: mechanism of tissue specificity and identification and characterization of cooperating tumorigenic pathways.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Animal Models Of Cancer; Brca1 Associated Cancer; Cancer; Medical Oncology; Oncogenes And Tumor Suppressor Genes; Rnai
Abstract
Breast cancer affects almost 23 000 Canadian women each year, and remains a major cause of death. Five percent all breast cancers, and 80% of inherited cases, are caused by mutations in the BRCA1 gene. Women who carry these mutations are also at high risk for the development of ovarian cancer, but not tumors at other sites. The reasons why individuals with these mutations develop cancers in these specific organs may be related to estrogen activity, but the mechanism of this process is not clear. Furthermore, abnormalities in BRCA1 function are found in a significant proportion of non-inherited breast cancers. They are especially common in a subset of tumors that do not respond to currently available targeted therapies (hormone therapies like tamoxifen, and treatments directed against HER2/neu, an abnormal tumor cell protein ie. Herceptin). The goals of this project are therefore to: (1) elucidate the molecular factors that contribute to the predisposition to breast and ovarian cancers in women who carry BRCA1 gene mutations; and (2) identify other molecular abnormalities that could be targeted for the treatment and/or prevention of these tumors. My research will use an animal model of BRCA1-associated breast cancer to explore these questions, and incorporate RNA interference (RNAi), a powerful new tool in molecular biology, to identify candidates for further characterization, validation, and study in patient samples. Collaboration with our clinical and drug development programs will enable us to use this model to explore new leads for future drug development in this population. This bench-to-bedside approach may result in effective new treatments for these difficult-to-treat cancers, potentially leading to improved survival or cure for women with this disease.
Competitiondate
200910
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Cescon, David W
Approvedterm
4 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $30,000~ $0~~ $90,000~ $0~